key: cord-0945662-q2eql9fg
authors: Mehta, Rajil B.; Silveira, Fernanda P.
title: COVID‐19 after two doses of mRNA vaccines in kidney transplant recipients
date: 2021-08-26
journal: Am J Transplant
DOI: 10.1111/ajt.16778
sha: 3526a28ba528c74a2e6fcaf020406c1eed36cfb9
doc_id: 945662
cord_uid: q2eql9fg

Mortality due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) among transplant recipients is high 1 . In December 2020 the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna) vaccines received emergency use authorization in the United States. These mRNA vaccines administered in a two-dose series were more than 94% effective in preventing COVID-19 in clinical trials, without safety concerns identified 2,3 . Transplant recipients were excluded from the clinical trials. Although decreased efficacy and immunogenicity were expected for transplant recipients, transplant recipients were included in the early vaccination prioritization groups and transplant societies, including the American Society of Transplantation, urged transplant recipients to get vaccinated as soon as vaccine was available.

To the Editor: 

COVID-19 in solid organ transplant: a multi-center cohort study

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Vaccination in immunocompromised patients: an observational, prospective cohort study interim analysis. medRxiv